124 related articles for article (PubMed ID: 38232332)
1. Hydrophobization of Ribonucleic Acids for Facile Systemic Delivery and Multifaceted Cancer Immunotherapy.
Zhang Y; Chen C; Su M; Wang J; Li C; Yang X
Nano Lett; 2024 Jan; 24(4):1376-1384. PubMed ID: 38232332
[TBL] [Abstract][Full Text] [Related]
2. Lipid-mediated delivery of CD47 siRNA aids JQ1 in ensuring simultaneous downregulation of PD-L1 and CD47 and improves antitumor immunotherapy efficacy.
Li Y; Meng X; Chen G; Hou Y; Wu X; Wang J; Cong X; Mao K; Wu C; Chen H; Sun X; Zhou J; Wang Y; Yang YG; Sun T
Biomater Sci; 2022 Nov; 10(23):6755-6767. PubMed ID: 36301154
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
[TBL] [Abstract][Full Text] [Related]
4. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
[TBL] [Abstract][Full Text] [Related]
5. Optimization of lipid assisted polymeric nanoparticles for siRNA delivery and cancer immunotherapy.
Lin S; Jing H; Du X; Yang X; Wang J
Biomater Sci; 2024 Apr; 12(8):2057-2066. PubMed ID: 38469870
[TBL] [Abstract][Full Text] [Related]
6. Polymer-lipid hybrid nanovesicle-enabled combination of immunogenic chemotherapy and RNAi-mediated PD-L1 knockdown elicits antitumor immunity against melanoma.
Wang C; Shi X; Song H; Zhang C; Wang X; Huang P; Dong A; Zhang Y; Kong D; Wang W
Biomaterials; 2021 Jan; 268():120579. PubMed ID: 33278683
[TBL] [Abstract][Full Text] [Related]
7. Lysosome activable polymeric vorinostat encapsulating PD-L1KD for a combination of HDACi and immunotherapy.
Lu F; Hou L; Wang S; Yu Y; Zhang Y; Sun L; Wang C; Ma Z; Yang F
Drug Deliv; 2021 Dec; 28(1):963-972. PubMed ID: 34036867
[TBL] [Abstract][Full Text] [Related]
8. Silencing of STAT3 via Peptidomimetic LNP-Mediated Systemic Delivery of RNAi Downregulates PD-L1 and Inhibits Melanoma Growth.
Ehexige E; Bao M; Bazarjav P; Yu X; Xiao H; Han S; Baigude H
Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32059541
[TBL] [Abstract][Full Text] [Related]
9. Bioactive fatty acid analog-derived hybrid nanoparticles confer antibody-independent chemo-immunotherapy against carcinoma.
Tan X; Wang C; Zhou H; Zhang S; Liu X; Yang X; Liu W
J Nanobiotechnology; 2023 Jun; 21(1):183. PubMed ID: 37291573
[TBL] [Abstract][Full Text] [Related]
10. Nanoparticle-based delivery strategies of multifaceted immunomodulatory RNA for cancer immunotherapy.
Yoo YJ; Lee CH; Park SH; Lim YT
J Control Release; 2022 Mar; 343():564-583. PubMed ID: 35124126
[TBL] [Abstract][Full Text] [Related]
11. Facile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic Delivery.
Xu C; Li D; Cao Z; Xiong M; Yang X; Wang J
Nano Lett; 2019 Apr; 19(4):2688-2693. PubMed ID: 30844291
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic delivery of siRNA silencing HIF-1 alpha with micellar nanoparticles inhibits hypoxic tumor growth.
Liu XQ; Xiong MH; Shu XT; Tang RZ; Wang J
Mol Pharm; 2012 Oct; 9(10):2863-74. PubMed ID: 22924580
[TBL] [Abstract][Full Text] [Related]
13. Molecular-Targeted Immunotherapeutic Strategy for Melanoma via Dual-Targeting Nanoparticles Delivering Small Interfering RNA to Tumor-Associated Macrophages.
Qian Y; Qiao S; Dai Y; Xu G; Dai B; Lu L; Yu X; Luo Q; Zhang Z
ACS Nano; 2017 Sep; 11(9):9536-9549. PubMed ID: 28858473
[TBL] [Abstract][Full Text] [Related]
14. Genome editing of PD-L1 mediated by nucleobase-modified polyamidoamine for cancer immunotherapy.
Wei S; Shao X; Liu Y; Xiong B; Cui P; Liu Z; Li Q
J Mater Chem B; 2022 Feb; 10(8):1291-1300. PubMed ID: 35141737
[TBL] [Abstract][Full Text] [Related]
15. Elaboration on the Distribution of Hydrophobic Segments in the Chains of Amphiphilic Cationic Polymers for Small Interfering RNA Delivery.
Wang C; Du L; Zhou J; Meng L; Cheng Q; Wang C; Wang X; Zhao D; Huang Y; Zheng S; Cao H; Zhang J; Deng L; Liang Z; Dong A
ACS Appl Mater Interfaces; 2017 Sep; 9(38):32463-32474. PubMed ID: 28862422
[TBL] [Abstract][Full Text] [Related]
16. In situ immunogenic clearance induced by a combination of photodynamic therapy and rho-kinase inhibition sensitizes immune checkpoint blockade response to elicit systemic antitumor immunity against intraocular melanoma and its metastasis.
Kim S; Kim SA; Nam GH; Hong Y; Kim GB; Choi Y; Lee S; Cho Y; Kwon M; Jeong C; Kim S; Kim IS
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33479026
[TBL] [Abstract][Full Text] [Related]
17. CXCR4-targeted nitric oxide nanoparticles deliver PD-L1 siRNA for immunotherapy against glioblastoma.
Hsieh HT; Huang HC; Chung CW; Chiang CC; Hsia T; Wu HF; Huang RL; Chiang CS; Wang J; Lu TT; Chen Y
J Control Release; 2022 Dec; 352():920-930. PubMed ID: 36334859
[TBL] [Abstract][Full Text] [Related]
18. Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.
Bocanegra Gondan AI; Ruiz-de-Angulo A; Zabaleta A; Gómez Blanco N; Cobaleda-Siles BM; García-Granda MJ; Padro D; Llop J; Arnaiz B; Gato M; Escors D; Mareque-Rivas JC
Biomaterials; 2018 Jul; 170():95-115. PubMed ID: 29656235
[TBL] [Abstract][Full Text] [Related]
19. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
[TBL] [Abstract][Full Text] [Related]
20. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
